Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Journal of Crohn's and Colitis Année : 2022

Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

Fichier non déposé

Dates et versions

hal-03665871 , version 1 (12-05-2022)

Identifiants

  • HAL Id : hal-03665871 , version 1

Citer

A. Buisson, M. Nachury, Mathurin Fumery, T. Guilmoteau, E. Leclerc, et al.. Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent. Journal of Crohn's and Colitis, 2022, 16 (1), pp.I120. ⟨hal-03665871⟩
22 Consultations
0 Téléchargements

Partager

Gmail Facebook Twitter LinkedIn More